Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...

Learn why the VictoryShares Dividend Accelerator ETF (VSDA) has underperformed its peers and why it may not be the best ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...